AstraZeneca Reports 12% Q4 Revenue Rise to $11.7B, Initiates $5B Buyback
AstraZeneca's Q4 revenue increased 12% to $11.7 billion, driven by oncology and cardiovascular segments. Adjusted EPS of $2.10 topped forecasts and the company approved a $5 billion share buyback and initiated a Phase III trial for a new heart failure drug.
1. Q4 Financial Performance
AstraZeneca posted Q4 2025 revenue of $11.7 billion, up 12% year-over-year, led by a 15% increase in oncology sales to $4.3 billion and a 10% rise in cardiovascular products to $2.8 billion.
2. Earnings and Capital Return
Adjusted EPS of $2.10 surpassed consensus by 8%, reflecting margin expansion; the board also authorized a $5 billion share repurchase to commence in Q2 2026.
3. Pipeline Advancement
The company initiated a global Phase III trial for AZD1234 in heart failure patients and expanded its immuno-oncology collaboration to explore bispecific antibodies.
4. Outlook and Guidance
Management reaffirmed a mid-single-digit revenue growth target for 2026 and earmarked $8 billion in R&D spending to support late-stage pipeline programs.